Latest filing published 08 Feb 2023 for Neurocrine Biosciences INC, €97k.
Filing timeline
BuySaleInsider track record
Malcolm Lloyd-Smith: trading record in brief
Malcolm Lloyd-Smith, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Neurocrine Biosciences Inc and Cadence Pharmaceuticals Inc. The record holds 73 filings, for trades running from 10 June 2013 to 8 February 2023.
The open-market record consists of 49 sales worth €16.7M, with no purchase. Other entries cover 1 share grant and 22 option exercises. Since January 2023: no purchases and 5 sales on the market.
Most recently, on 8 February 2023, the filings show an open-market sale worth €97k in Neurocrine Biosciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Malcolm Lloyd-Smith
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,015 shares@ US$102.160.5% of flowCommon StockSEC:0001209191-23-007914:1
- 12,801 shares@ US$102.415.9% of flowCommon StockSEC:0001209191-23-007914:2
- 701 shares@ US$103.830.3% of flowCommon StockSEC:0001209191-23-007914:3
- 801 shares@ US$105.81533.3% of flowCommon StockSEC:0001209191-23-007914:0
- 1,666 shares@ US$110.01837.1% of flowCommon StockSEC:0001209191-23-006280:0
- 21,533 shares@ US$105.9510.6% of flowCommon StockSEC:0001209191-22-046070:1
- 3,455 shares@ US$35.990.6% of flowCommon StockSEC:0001209191-22-046070:2
- 3,361 shares@ US$43.240.7% of flowCommon StockSEC:0001209191-22-046070:3
- 1,227 shares@ US$81.490.5% of flowCommon StockSEC:0001209191-22-046070:4
- 21,533 shares@ US$35.9931.5% of flowCommon StockSEC:0001209191-22-046070:0
- 1,015 shares@ US$80.730.3% of flowCommon StockSEC:0001209191-22-008214:1
- 801 shares@ US$80.650.3% of flowCommon StockSEC:0001209191-22-008214:2
- 701 shares@ US$79.530.2% of flowCommon StockSEC:0001209191-22-008214:3
- 865 shares@ US$80.78142.6% of flowCommon StockSEC:0001209191-22-008214:0
- 16,709 shares@ US$93.801955.6% of flowCommon StockSEC:0001209191-21-048560:0
- 1,100 shares@ US$35.990.2% of flowCommon StockSEC:0001209191-21-010498:0
- 1,100 shares@ US$119.960.7% of flowCommon StockSEC:0001209191-21-010498:1
- 600 shares@ US$35.990.1% of flowCommon StockSEC:0001209191-21-010498:2
- 600 shares@ US$119.950.4% of flowCommon StockSEC:0001209191-21-010498:3
- 865 shares@ US$114.150.5% of flowCommon StockSEC:0001209191-21-009121:0
- 756 shares@ US$116.890.4% of flowCommon StockSEC:0001209191-21-009121:1
- 1,490 shares@ US$116.740.9% of flowCommon StockSEC:0001209191-21-009121:2
- 1,015 shares@ US$116.870.6% of flowCommon StockSEC:0001209191-21-009121:3
- 4,011 shares@ US$35.990.7% of flowCommon StockSEC:0001209191-21-005820:0
- 4,011 shares@ US$119.982.4% of flowCommon StockSEC:0001209191-21-005820:1
25 of 73 declarations
